REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM MONORAIL AND OVER THE WIRE
Boston Scientific Corp · Decision date Mar 10, 2026
What did the FDA approve?
FDA records P130030 as an original PMA application. The recorded decision is approval, dated Mar 10, 2026.
FDA approval order statement
APPROVAL FOR THE REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE). THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH DE NOVO LESIONS <= 28 MM IN LENGTH IN NATIVE CORONARY ARTERIES WITH A REFERENCE VESSEL DIAMETER (RVD) OF >= 2.25 TO >= 4.50 MM.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 10, 2026
Regulatory record facts
- Identifier
- P130030
- Regulatory pathway
- Premarket approval application
- Applicant
- Boston Scientific Corp
- Product code
- MAF
- Decision code
- APPR
- Decision date
- Mar 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, CORONARY.
- Applicant
- Boston Scientific Corp
- Product code
- MAF
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P130030 received
Application receipt date recorded by FDA.
P130030 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P130030. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MAF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PRO-Kinetic Energy Coronary Stent SystemP160003/S024 | Biotronik AG | PMA supplement | Jun 5, 2026 | FDA |
PRO-Kinetic Energy Coronary Stent SystemP160003/S022 | Biotronik AG | PMA supplement | Apr 15, 2026 | FDA |
PRO-Kinetic Energy Coronary Stent SystemP160003/S026 | Biotronik AG | PMA supplement | Apr 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P130030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

